FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510050480> ?p ?o ?g. }

• W2510050480 abstract "Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) signaling is central in various cancers, but the relevance of EPOR signaling in multiple myeloma cells has not yet been thoroughly investigated.Myeloma cell lines and malignant plasma cells isolated from bone marrow of myeloma patients were used in this study. Transcript levels were analysed by quantitative PCR and cell surface levels of EPOR in primary cells by flow cytometry. Knockdown of EPOR by short interfering RNA was used to show specific EPOR signaling in the myeloma cell line INA-6. Flow cytometry was used to assess viability in primary cells treated with EPO in the presence and absence of neutralizing anti-EPOR antibodies. Gene expression data for total therapy 2 (TT2), total therapy 3A (TT3A) trials and APEX 039 and 040 were retrieved from NIH GEO omnibus and EBI ArrayExpress.We show that the EPOR is expressed in myeloma cell lines and in primary myeloma cells both at the mRNA and protein level. Exposure to recombinant human EPO (rhEPO) reduced viability of INA-6 myeloma cell line and of primary myeloma cells. This effect could be partially reversed by neutralizing antibodies against EPOR. In INA-6 cells and primary myeloma cells, janus kinase 2 (JAK-2) and extracellular signal regulated kinase 1 and 2 (ERK-1/2) were phosphorylated by rhEPO treatment. Knockdown of EPOR expression in INA-6 cells reduced rhEPO-induced phospo-JAK-2 and phospho-ERK-1/2. Co-cultures of primary myeloma cells with bone marrow-derived stroma cells did not protect the myeloma cells from rhEPO-induced cell death. In four different clinical trials, survival data linked to gene expression analysis indicated that high levels of EPOR mRNA were associated with better survival.Our results demonstrate for the first time active EPOR signaling in malignant plasma cells. EPO-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro. Our results encourage further studies to investigate the importance of EPO/EPOR in multiple myeloma progression and treatment.[Trial registration number for Total Therapy (TT) 2: NCT00083551 and TT3: NCT00081939 ]." @default.
• W2510050480 created "2016-09-16" @default.
• W2510050480 creator A5001958312 @default.
• W2510050480 creator A5004995665 @default.
• W2510050480 creator A5009564890 @default.
• W2510050480 creator A5025851882 @default.
• W2510050480 creator A5039381752 @default.
• W2510050480 creator A5041097509 @default.
• W2510050480 creator A5051008993 @default.
• W2510050480 creator A5055459709 @default.
• W2510050480 creator A5056712587 @default.
• W2510050480 date "2016-08-31" @default.
• W2510050480 modified "2023-10-18" @default.
• W2510050480 title "Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro" @default.
• W2510050480 cites W1528235627 @default.
• W2510050480 cites W1979652151 @default.
• W2510050480 cites W1982410732 @default.
• W2510050480 cites W1997001746 @default.
• W2510050480 cites W1999784325 @default.
• W2510050480 cites W2005100560 @default.
• W2510050480 cites W2013877595 @default.
• W2510050480 cites W2021063479 @default.
• W2510050480 cites W2024004416 @default.
• W2510050480 cites W2028051225 @default.
• W2510050480 cites W2028827702 @default.
• W2510050480 cites W2044804580 @default.
• W2510050480 cites W2045175259 @default.
• W2510050480 cites W2051390434 @default.
• W2510050480 cites W2077995274 @default.
• W2510050480 cites W2080302923 @default.
• W2510050480 cites W2082621960 @default.
• W2510050480 cites W2083029419 @default.
• W2510050480 cites W2084223483 @default.
• W2510050480 cites W2090972327 @default.
• W2510050480 cites W2103114868 @default.
• W2510050480 cites W2125723884 @default.
• W2510050480 cites W2135198134 @default.
• W2510050480 cites W2136373453 @default.
• W2510050480 cites W2138343003 @default.
• W2510050480 cites W2144296845 @default.
• W2510050480 cites W2158333823 @default.
• W2510050480 cites W2160618879 @default.
• W2510050480 cites W2160690175 @default.
• W2510050480 cites W2325515483 @default.
• W2510050480 cites W2397324258 @default.
• W2510050480 cites W2463368821 @default.
• W2510050480 cites W2506648470 @default.
• W2510050480 cites W34534769 @default.
• W2510050480 cites W4256003647 @default.
• W2510050480 doi "https://doi.org/10.1186/s13045-016-0306-x" @default.
• W2510050480 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5007700" @default.
• W2510050480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27581518" @default.
• W2510050480 hasPublicationYear "2016" @default.
• W2510050480 type Work @default.
• W2510050480 sameAs 2510050480 @default.
• W2510050480 citedByCount "9" @default.
• W2510050480 countsByYear W25100504802017 @default.
• W2510050480 countsByYear W25100504802018 @default.
• W2510050480 countsByYear W25100504802019 @default.
• W2510050480 countsByYear W25100504802020 @default.
• W2510050480 countsByYear W25100504802021 @default.
• W2510050480 countsByYear W25100504802022 @default.
• W2510050480 crossrefType "journal-article" @default.
• W2510050480 hasAuthorship W2510050480A5001958312 @default.
• W2510050480 hasAuthorship W2510050480A5004995665 @default.
• W2510050480 hasAuthorship W2510050480A5009564890 @default.
• W2510050480 hasAuthorship W2510050480A5025851882 @default.
• W2510050480 hasAuthorship W2510050480A5039381752 @default.
• W2510050480 hasAuthorship W2510050480A5041097509 @default.
• W2510050480 hasAuthorship W2510050480A5051008993 @default.
• W2510050480 hasAuthorship W2510050480A5055459709 @default.
• W2510050480 hasAuthorship W2510050480A5056712587 @default.
• W2510050480 hasBestOaLocation W25100504801 @default.
• W2510050480 hasConcept C134018914 @default.
• W2510050480 hasConcept C203014093 @default.
• W2510050480 hasConcept C2776364478 @default.
• W2510050480 hasConcept C2778534260 @default.
• W2510050480 hasConcept C2780007613 @default.
• W2510050480 hasConcept C31102739 @default.
• W2510050480 hasConcept C502942594 @default.
• W2510050480 hasConcept C54355233 @default.
• W2510050480 hasConcept C553184892 @default.
• W2510050480 hasConcept C71924100 @default.
• W2510050480 hasConcept C81885089 @default.
• W2510050480 hasConcept C86803240 @default.
• W2510050480 hasConceptScore W2510050480C134018914 @default.
• W2510050480 hasConceptScore W2510050480C203014093 @default.
• W2510050480 hasConceptScore W2510050480C2776364478 @default.
• W2510050480 hasConceptScore W2510050480C2778534260 @default.
• W2510050480 hasConceptScore W2510050480C2780007613 @default.
• W2510050480 hasConceptScore W2510050480C31102739 @default.
• W2510050480 hasConceptScore W2510050480C502942594 @default.
• W2510050480 hasConceptScore W2510050480C54355233 @default.
• W2510050480 hasConceptScore W2510050480C553184892 @default.
• W2510050480 hasConceptScore W2510050480C71924100 @default.
• W2510050480 hasConceptScore W2510050480C81885089 @default.
• W2510050480 hasConceptScore W2510050480C86803240 @default.
• W2510050480 hasFunder F4320310758 @default.
• W2510050480 hasFunder F4320322752 @default.
• W2510050480 hasFunder F4320332161 @default.

• next